FOLR1 and ovarian carcinoma: Thus, mirvetuximab soravtansine is an effective and well-tolerated therapeutic option for patients with platinum-resistant ovarian cancer and high FRα expression, enhancing the therapeutic arsenal in this challenging clinical setting.